Canada NewsWire
VANCOUVER, March 10, 2017
NASDAQ: NVCN
TSX: NVC
VANCOUVER, March 10, 2017 /CNW/ - Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that effective at the opening of trading on
Monday, March 13, 2017, shares of Neovasc will commence trading on the Toronto Stock Exchange
("TSX") under the symbol NVCN.
Following this change, the Company's TSX and Nasdaq Stock Market symbols will be the same. No action is required to be
taken by current shareholders in connection with the change.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not
currently available in the U.S. and has been available in Europe since 2015 and the Tiara™, for
the transcatheter treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells a line of advanced biological
tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more
information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/March2017/10/c6795.html